These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35129294)

  • 21. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.
    Gupta AA; Xue W; Harrison DJ; Hawkins DS; Dasgupta R; Wolden S; Shulkin B; Qumseya A; Routh JC; MacDonald T; Feinberg S; Crompton B; Rudzinski ER; Arnold M; Venkatramani R
    Lancet Oncol; 2024 Jul; 25(7):912-921. PubMed ID: 38936378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma.
    Dehner CA; Armstrong AE; Yohe M; Shern JF; Hirbe AC
    Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
    Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
    J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extremity Rhabdomyosarcoma-An Integrated Clinicopathologic and Genomic Study to Improve Risk Stratification.
    de Traux de Wardin H; Xu B; Dermawan JK; Smith MH; Wolden SL; Antonescu CR; Wexler LH
    JCO Precis Oncol; 2023 Jun; 7(1):e2200705. PubMed ID: 37315267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group.
    Milewski D; Jung H; Brown GT; Liu Y; Somerville B; Lisle C; Ladanyi M; Rudzinski ER; Choo-Wosoba H; Barkauskas DA; Lo T; Hall D; Linardic CM; Wei JS; Chou HC; Skapek SX; Venkatramani R; Bode PK; Steinberg SM; Zaki G; Kuznetsov IB; Hawkins DS; Shern JF; Collins J; Khan J
    Clin Cancer Res; 2023 Jan; 29(2):364-378. PubMed ID: 36346688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group.
    Crane JN; Xue W; Qumseya A; Gao Z; Arndt CAS; Donaldson SS; Harrison DJ; Hawkins DS; Linardic CM; Mascarenhas L; Meyer WH; Rodeberg DA; Rudzinski ER; Shulkin BL; Walterhouse DO; Venkatramani R; Weiss AR
    Pediatr Blood Cancer; 2022 Jun; 69(6):e29644. PubMed ID: 35253352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials.
    Selfe J; Olmos D; Al-Saadi R; Thway K; Chisholm J; Kelsey A; Shipley J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies.
    Schloemer NJ; Xue W; Qumseya A; Luo LY; Hiniker SM; Lautz TB; Rhee DS; Arnold MA; Venkatramani R
    Pediatr Blood Cancer; 2024 Oct; 71(10):e31200. PubMed ID: 39016936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genitourinary rhabdomyosarcoma: which treatment, how much, and when?
    Wu HY; Snyder HM; Womer RB
    J Pediatr Urol; 2009 Dec; 5(6):501-6. PubMed ID: 19640790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    Meza JL; Anderson J; Pappo AS; Meyer WH;
    J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Vasquez JC; Luo LY; Hiniker SM; Rhee DS; Dasgupta R; Chen S; Weigel BJ; Xue W; Venkatramani R; Arndt CA
    Pediatr Blood Cancer; 2023 Jun; 70(6):e30293. PubMed ID: 36916768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Martin-Giacalone BA; Li H; Scheurer ME; Casey DL; Dugan-Perez S; Marquez-Do DA; Muzny D; Gibbs RA; Barkauskas DA; Hall D; Stewart DR; Schiffman JD; McEvoy MT; Khan J; Malkin D; Linardic CM; Crompton BD; Shern JF; Skapek SX; Venkatramani R; Hawkins DS; Sabo A; Plon SE; Lupo PJ
    JAMA Netw Open; 2024 Mar; 7(3):e244170. PubMed ID: 38546643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
    Casey DL; Chi YY; Donaldson SS; Hawkins DS; Tian J; Arndt CA; Rodeberg DA; Routh JC; Lautz TB; Gupta AA; Yock TI; Wolden SL
    Cancer; 2019 Sep; 125(18):3242-3248. PubMed ID: 31174239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Abbou S; Klega K; Tsuji J; Tanhaemami M; Hall D; Barkauskas DA; Krailo MD; Cibulskis C; Nag A; Thorner AR; Pollock S; Imamovic-Tuco A; Shern JF; DuBois SG; Venkatramani R; Hawkins DS; Crompton BD
    J Clin Oncol; 2023 May; 41(13):2382-2393. PubMed ID: 36724417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.
    Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rhabdomyosarcoma: current challenges and their implications for developing therapies.
    Hettmer S; Li Z; Billin AN; Barr FG; Cornelison DD; Ehrlich AR; Guttridge DC; Hayes-Jordan A; Helman LJ; Houghton PJ; Khan J; Langenau DM; Linardic CM; Pal R; Partridge TA; Pavlath GK; Rota R; Schäfer BW; Shipley J; Stillman B; Wexler LH; Wagers AJ; Keller C
    Cold Spring Harb Perspect Med; 2014 Nov; 4(11):a025650. PubMed ID: 25368019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Rudzinski ER; Teot LA; Anderson JR; Moore J; Bridge JA; Barr FG; Gastier-Foster JM; Skapek SX; Hawkins DS; Parham DM
    Am J Clin Pathol; 2013 Jul; 140(1):82-90. PubMed ID: 23765537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on pediatric rhabdomyosarcoma: A report from the APSA Cancer Committee.
    Rhee DS; Rodeberg DA; Baertschiger RM; Aldrink JH; Lautz TB; Grant C; Meyers RL; Tracy ET; Christison-Lagay ER; Glick RD; Mattei P; Dasgupta R;
    J Pediatr Surg; 2020 Oct; 55(10):1987-1995. PubMed ID: 32674846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular diagnostics in the management of rhabdomyosarcoma.
    Arnold MA; Barr FG
    Expert Rev Mol Diagn; 2017 Feb; 17(2):189-194. PubMed ID: 28058850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.